Researchers at The Jackson Laboratory (JAX) reported an epigenetic approach that reactivates a tumor suppressor gene in acute myeloid leukemia models. In mouse experiments published in Science Translational Medicine, the team linked reduced activity of ZBTB7A to KDM4-driven chromatin silencing and showed that KDM4 inhibition restored ZBTB7A expression and reduced leukemia burden without largely disrupting normal blood formation. The work used a mapping tool called FISHnCRISP—combining fluorescence in situ hybridization, flow cytometry, and CRISPR editing—to identify gene-silencing states in AML cells from patients. The mechanistic readout centered on regulatory tail length, recruitment by ZFP36L2, and KDM4 enzyme activity. For AML drug development, the strategy shifts part of the therapeutic goal from killing cells to restoring suppressed pathways—an approach that may open combination options and biomarker-driven patient selection.